Cargando…

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

OBJECTIVES: Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin. We aimed to evaluate efficacy and safety of 600 versus 800 mg of efavirenz in tuberculosis/HIV patients using rifampicin. DESIGN: We conducted an open label, multicentre, randomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xavier, Mariana S., Trajman, Anete, Schmaltz, Carolina A. S., Sant'anna, Flavia M., Maia, Ivan R., Hadad, David J., do Brasil, Pedro Emmanuel A. A., Rolla, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354140/ https://www.ncbi.nlm.nih.gov/pubmed/30792988 http://dx.doi.org/10.1155/2018/9231835

Ejemplares similares

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
por: Dickinson, L, et al.
Publicado: (2015)

Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
por: Carey, Dianne
Publicado: (2014)

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens
por: da Silva, Tatiana P., et al.
Publicado: (2013)

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
por: Seden, Kay, et al.
Publicado: (2018)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Appropriate clinical use of darunavir 800 mg
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2021)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
por: Dickinson, Laura, et al.
Publicado: (2015)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014
por: Cardoso, Mayara A., et al.
Publicado: (2017)

Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily
por: Kanakia, Rajendra, et al.
Publicado: (2008)

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni, Soujanya, et al.
Publicado: (2017)

Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
por: Cakal, Sinem, et al.
Publicado: (2021)

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study
por: Fogarty, Charles M, et al.
Publicado: (2005)

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents
por: MacDonald, T M, et al.
Publicado: (2010)

Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
por: Dravid, Ameet, et al.
Publicado: (2022)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis
por: Hawthorne, A Barney, et al.
Publicado: (2012)

Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study
por: Steinbruch, Marcio, et al.
Publicado: (2020)

Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
por: Iizuka, Tomomichi, et al.
Publicado: (2017)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
por: Dravid, A, et al.
Publicado: (2020)

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis
por: Kendall, Emily A., et al.
Publicado: (2021)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil
por: Demitto, Fernanda O., et al.
Publicado: (2019)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery
por: Carbonell Esteve, Josep L, et al.
Publicado: (2012)

Practical guide to choosing dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with atrial fibrillation
por: Kobayashi, Zen, et al.
Publicado: (2019)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Influence of the Efavirenz Micronization on Tableting and Dissolution
por: Pinto, Eduardo Costa, et al.
Publicado: (2012)

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses
por: Hobson, Alex R., et al.
Publicado: (2010)

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
por: Schalkwijk, Stein, et al.
Publicado: (2018)

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV
por: Demitto, Fernanda O., et al.
Publicado: (2020)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5o85a6p9mclr88f4o2pl4rf8mu